

Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia

Justine Brodard^{*}, *Lorenzo Alberio*^{†‡}, *Anne Angelillo-Scherrer*^{*§}, and *Michael Nagler*^{*¶}

Affiliations:

^{*} Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

[†] Division of Hematology and Central Hematology Laboratory, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

[‡] Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

[§] Department for BioMedical Research, University of Bern, Bern, Switzerland

[¶] University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Correspondence to:

Michael Nagler, MD, PhD, MSc
University Institute of Clinical Chemistry, Inselspital, Bern
University Hospital, and University of Bern, Bern, Switzerland
Freiburgerstrasse
3010 Bern
Telefon: +41 31 632 24 05
Michael.nagler@insel.ch

Short title: Diagnostic accuracy of heparin-induced platelet aggregation test

Abstract/ Text: 250 words / 2049 words

Tables/ Figures: 1/2

References: 13

1 Summary

2 Introduction

3 Whereas the utility of washed platelet assays such as the heparin-induced platelet activation
4 test (HIPA) for the diagnosis of heparin-induced thrombocytopenia (HIT) is regarded as high,
5 the performance of simpler assays such as the heparin-induced platelet aggregation test (PAT)
6 is still elusive. Using well-characterized samples of a large cohort study, we aimed to assess
7 the diagnostic accuracy of PAT for the diagnosis of HIT.

8 Material and Methods

9 One-hundred twenty-two immunoassay-positive serum samples of a previous, prospective
10 single-center cohort study including consecutive patients with suspected HIT (n=1291) were
11 used. HIPA was determined as reference gold standard; samples were previously analyzed
12 using PAT as well as polyspecific platelet factor 4/heparin enzyme-linked immunosorbent
13 assay (ELISA). 4Ts score was calculated using the patient documentation. Diagnosis of HIT was
14 defined as a positive HIPA, which is a positive reaction in 2 out of 4 donor platelets within 30
15 minutes.

16 Results

17 HIT was diagnosed in 39 out of 122 patients corresponding to a prevalence of 32%. Median
18 optical density (ELISA) was 2.8 (inter-quartile range 2.3, 3.0) in patients with HIT and 0.7 (0.5,
19 1.3) in patients without HIT. PAT was positive in 27 out of 39 HIT patients and it was negative
20 in 83 out of 83 HIT-negative patients. Thus, the sensitivity of PAT for the diagnosis of HIT was
21 69% (95% confidence interval 52%, 83%) and the specificity 100% (96%, 100%).

22 Conclusions

23 Our results demonstrate that PAT is a valuable test to confirm HIT but cannot be applied to
24 rule-out HIT in clinical practice.

25 **Key words:** Heparin-induced thrombocytopenia;
26 Heparin/adverse effects;
27 thrombocytopenia/chemically induced;
28 thrombocytopenia/diagnosis;
29 immunoassay/methods;
30

1 Introduction

2 Diagnosing heparin-induced thrombocytopenia (HIT) is challenging. A number of diagnostic
3 tests are available, but all are associated with certain drawbacks [1, 2]. Clinical assessment
4 tools like the 4Ts score can be applied during weekends and nightshifts, but these tests are
5 observer-dependent, and the diagnostic accuracy is clearly restricted [3]. Immunoassays such
6 as platelet factor 4[PF4]/heparin enzyme-linked immunosorbent assay (ELISA) are able to
7 demonstrate anti-heparin/PF4 antibodies with a high sensitivity [1], but they can hardly
8 differentiate antibodies which activate platelets and other that do not [4-6]. In addition, the
9 diagnostic accuracy varies according to type of antibody specificity, thresholds, and
10 manufacturer. Platelet-activating antibodies, which are able to cause clinical HIT, can be
11 demonstrated using functional assays only [4, 7].

12 Washed-platelet assays, such as serotonin release assay (SRA) or heparin-induced platelet
13 activation test (HIPA) are regarded as gold-standard tests for the diagnosis of HIT [8].
14 However, SRA and washed-platelet HIPA are complicated, time-consuming and require a
15 highly specialized laboratory [8]. Thus, results are rarely available in a timely manner [1]. A
16 number of other functional assays have been developed to overcome these limitations. The
17 first functional test for HIT was the heparin-induced platelet aggregation test (PAT) done on
18 platelet-rich plasma (PRP) [1, 9]. PAT done on PRP is a promising assay because it can be
19 conducted using light transmission aggregometers, which are available in many laboratories,
20 and utilizing PRP, which avoids platelet-washing procedures and handling of radioactive
21 agents [4]. A number of authors proposed and used PAT done on PRP for diagnosis of HIT [9-
22 13]. However, the diagnostic accuracy of PAT done on PRP for HIT is still not fully established
23 [1].


24 Using well-characterized samples of a large single-centre cohort study, we aimed to assess the
25 diagnostic accuracy of PAT done on PRP for the diagnosis of HIT.

26 Methods

27 Design, setting and population

28 The design of the study is shown in Figure 1. We used patient data and remaining samples of
29 a previous single-centre cohort study [10], in which 1291 consecutive patients were included,
30 representing a mixed population (53.5% internal medicine, 23.5% surgery including cardiac
31 surgery, and 20.1% intensive care unit). Median age was 67.9 years (inter-quartile range [IQR]:
32 1.5-106.4) and 43.8% of the patients were female. Inclusion criteria were “suspected HIT”
33 corresponding to a requested HIT test or a requested consultancy service (4Ts score obtained).
34 Clinical data were obtained as well prospectively as retrospectively (4T’s score in some
35 patients), and a number of laboratory tests were conducted: particle gel immunoassay (ID-
36 H/PF4 PaGIA; DiaMed SA, Cressier sur Morat, Switzerland), polyspecific heparin/PF4-ELISA
37 (GTI Diagnostics, Waukesha, WI, USA), and PAT done in PRP (conducted in all patients). The
38 detailed characteristics with regard to patients, setting, determination of laboratory tests, and
39 collection of clinical data are described in detail elsewhere [10].

1 For the purpose of the present investigation, we randomly selected 122 patient samples with
2 remaining serum or plasma samples and positive immunoassay out of the study cohort
3 mentioned above, the inclusion criteria was a positive immunoassay (optical density [OD] of
4 ELISA ≥ 0.4 and/or positive PaGIA). Washed-platelet HIPA was conducted between March and
5 June 2017. Presence of HIT was defined as a positive washed-platelet HIPA, determined as
6 described below. The number of samples drawn from the previous cohort study was based on
7 practicability issues and availability of remaining samples rather than a full power analysis.
8 The study was approved by the appropriate ethical committee (#1900476).



9 **Figure 1 | Design of the current cohort study. Abbreviations:** HIT, heparin-induced
10 thrombocytopenia; HIPA, washed platelet heparin-induced platelet activation test; PAT,
11 heparin-induced platelet aggregation test done on platelet-rich plasma; PaGIA, particle gel
12 immunoassay (PaGIA); OD, optical density.

1 **Determination of PAT done on PRP**

2 PAT done on PRP was conducted as previously described [9]. Briefly, PRP of four selected
3 donors was incubated with platelet poor plasma of the patient in presence of three different
4 heparin solutions: 0.5 U/ml UFH, 0.5 U/ml low molecular weight heparin (LMWH; nadroparin),
5 as well as 100 U/ml unfractionated Heparin (UFH Liquemin®). Similar to previous publications,
6 four healthy donors were selected in order to account for accidental effects that inhibit or
7 stimulate platelet activation [9, 12]. Donors were selected if previous aggregation studies
8 demonstrated platelet aggregation in presence of HIT-sera. Light transmission was
9 determined using an aggregometer (APACT 4004, LABiTec, Ahrensburg, Germany) for 15
10 minutes. PAT done on PRP was considered as positive if aggregation was at least 50% in two
11 out of four selected donors (using low concentrations of UFH or LMWH respectively), and if
12 the reaction could be suppressed by high concentrations of UFH.

13 **Collection and storage of samples**

14 A standardized protocol for blood withdrawal was implemented to ensure adequate pre-
15 analytic conditions. Plasma samples were collected into 3.2% sodium citrate (10mL, S-
16 Monovette, Sarstedt Nümbrecht, Germany). Platelet-poor plasma was obtained by double
17 centrifugation at 1500x g for 10min at room temperature. Serum and plasma samples were
18 snap-frozen and stored in polypropylenes tube at -80°C [10].

19 **Preparation of samples and determination of washed-platelet HIPA**

20
21 To generate washed platelets, whole blood of five unselected healthy donors was collected
22 into acid-citrate-dextrose solution (ACD) to prevent platelet aggregation and to bind residual
23 calcium [4, 11]. PRP was produced by a low speed centrifugation scheme without break (120g
24 for 20 minutes) and platelets were washed in two steps. First, the platelet pellet was re-
25 suspended in calcium and magnesium-free Tyrode's buffer at pH 6.3 adding glucose and
26 apyrase. The second pellet was re-suspended using calcium- and magnesium-containing
27 Tyrode's buffer at pH 7.2. Afterwards, platelet suspension was incubated at 37°C for 45
28 minutes [4, 8, 11].

29 Patient's samples were thawed for 5 minutes at 37°C and heated at 56°C for 45 minutes to
30 inactivate residual thrombin. The following substances were added into the designed wells of
31 a 96-well microplate: 10 µL of suspension buffer, a low concentration of LMWH (Reviparin)
32 (0.2U/ml), a high concentration of UFH (Liquemin®) 100 U/ml, 20 µL patient's serum, and 75
33 µL platelet's suspension. Thereafter the microplate was incubated for 45 minutes on a
34 magnetic stirrer plate, stirring two steel balls per well at high speed (600 rotations per minute).
35 Platelet activation was observed by monitoring translucent transformation. The test is
36 considered positive if platelet activation occurs in at least 2 out of 4 platelet donors using
37 LMWH but not UFH after not more than 30 minutes [4, 8, 11].

38

39 **Statistical analysis**

40 Descriptive statistics were used to characterize the study population and describe the
41 distribution of test results (median and inter-quartile range [IQR]/ ranges or frequencies as

1 appropriate). Two-by-two tables were generated by stating true positives, false positives, false
 2 negatives, and true negatives. Diagnostic accuracy of PAT done on PRP was determined by
 3 calculating the sensitivity, the specificity and the likelihood ratio in relation to the presence of
 4 HIT (defined as a positive washed platelet HIPA test). Analyses were performed using the Stata
 5 14.1 statistic software package (StataCorp. 2014. Stata Statistical Software: Release 14.
 6 College Station, TX: StataCorp LP).

7 Results

8 One-hundred twenty-two patient samples with a positive immunoassay test result were
 9 analyzed. Detailed patient characteristics according to the presence of HIT are shown in
 10 Table 1. Median age was 70 years, IQR 60 to 77. Fifty-one of the patients were female
 11 (41.8%). ELISA was positive in all patients and PaGIA was positive in 112 patients.

12 Presence of HIT was confirmed by a positive washed-platelet HIPA in 39 patients, the
 13 prevalence in the cohort was 32%. Median 4Ts score was 4.5 in patients with HIT (IQR 4, 5),
 14 and 3 in patients without HIT (IQR 2 to 4). Median OD of ELISA was 2.8 in patients with HIT
 15 (IQR 2.3, 3.0) compared to 0.7 in patients without (IQR 0.5, 1.3).

16 Figure 2 shows the contingency table illustrating the diagnostic accuracy of PAT done on
 17 PRP. The sensitivity was 69% (95% CI 52%, 83%) and the specificity 100% (95% CI 96%,
 18 100%). The corresponding positive likelihood ratio was 116 (95% CI 7, 1846) and the negative
 19 likelihood ratio 0.3 (95% CI 0.2, 0.5).

	HIT positive n=39 (32%)	HIT negative n=83 (68%)	All patients n=122 (100%)
Age in years , median (IQR)	70 (62, 77)	68 (55, 77)	70 (60, 77)
Sex , numbers (%)			
Male	21 (17.2)	50 (40.1)	71 (58.2)
Female	18 (14.8)	33 (27.0)	51 (41.8)
4T's score , median (IQR)	4.5 (4, 5)	3 (2, 4)	4 (3, 5)
Polyspecific GTI ELISA , median OD (IQR)	2.84 (2.30, 3.01)	0.71 (0.53, 1.34)	1.12 (0.62, 2.32)
PaGIA , median titre (IQR)	8 (4, 32)	0 (0, 2)	1 (0, 8)

20 **Table 1 | Baseline characteristics of the current study cohort (n=122).** A random sample of
 21 patients with a positive ELISA or PaGIA result respectively was drawn out of the population
 22 of a previously conducted large cohort study [8]. Presence of HIT was defined as a positive
 23 heparin-induced platelet activation test (washed-platelet HIPA). Abbreviations: HIT, heparin-
 24 induced thrombocytopenia; IQR, interquartile range; OD, optical density; ELISA, enzyme-
 25 linked immunosorbent assay; PaGIA, particle gel immunoassay

26

PAT done on PRP (Index test)	HIT (Numbers of patients)		Total	Prevalence 32%
	Positive	Negative		
Positive	27	0	27	PPV 100% (95% CI 77%, 100%)
Negative	12	83	95	NPV 87% (95% CI 81%, 92%)
Total	39	83		
	Sensitivity 69% (95% CI 52%, 83%)	Specificity 100% (95% CI 96%, 100%)	LR+ 116 (95% CI 7, 1846)	LR- 0.3 (95% CI 0.2, 0.5)

1 **Figure 2 | Contingency table illustrating the diagnostic accuracy of PAT done on PRP for the**
2 **presence of HIT.** Presence of HIT was defined as a positive washed-platelet HIPA assay.
3 Abbreviations: HIT, heparin-induced thrombocytopenia; PAT done on PRP, heparin-induced
4 platelet aggregation test; washed-platelet HIPA, heparin-induced platelet activation test
5 using washed platelets; PPV, positive predictive value; NPV, negative predictive value; LR+,
6 positive likelihood ratio; LR-, negative likelihood ratio

7 Discussion

8 Using samples and patient data of a previous, prospective single-center cohort study, we
9 observed a clearly inferior sensitivity of PAT done on PRP compared to washed-platelet HIPA.
10 In contrast, specificity was excellent. However, in view of the high risk of thromboembolism
11 in patients with a missed diagnosis of HIT, a test with a limited sensitivity is not useful in clinical
12 practice.

13 Even though previous investigations differ in characteristics of the patients and samples, and
14 determination of PAT done on PRP vary among centers, our results are in-line with previous
15 investigations. Chong and colleagues reported a sensitivity between 65% and 94% depending
16 on the reactivity of the platelets [12]. Sensitivity of PAT done on PRP was clearly inferior to
17 washed-platelet HIPA in 209 samples of patients with suspected HIT [11]. In accordance with

1 our results, all patients with a positive PAT done on PRP results had a positive washed-platelet
2 HIPA result as well. In a study done by Favaloro and colleagues in 140 selected samples,
3 sensitivity of PAT done on PRP was inferior to SRA but specificity was high [13].

4 The strength of our investigation is that we studied 122 samples of well-characterized
5 patients, included in a previous prospective cohort study [10]. Only immunoassay-positive
6 samples were included, resulting in a comparable high prevalence of 32%. Thus, the present
7 cohort constitutes an appropriate representation of the target population of a functional
8 assay for HIT. Our study has limitations as well. First, the samples were stored at -80°C for
9 several years. Even though pilot studies did not indicate significant changes in antibody activity
10 over time, we cannot fully exclude minor effects. Second, the number of samples used was
11 more based on practicability issues and the availability of residual material rather than a full
12 power analysis. However, with a view on the confidence intervals determined, we do not
13 believe that a larger study population would have changed the results. Third, data on clinical
14 endpoints supporting or contradicting the diagnostic classification as done by HIPA are not
15 available within the present database.

16 In conclusion, our results confirm that PAT done on PRP is an appropriate test to verify a HIT-
17 positive sample for scientific purposes. However, the sensitivity is clearly limited and it is not
18 possible to rule-out HIT in clinical practice.

19 Addendum

20 MN designed the study, analysed the data, and wrote the manuscript. JB conducted the
21 analyses, analysed the data, and wrote the manuscript. LA designed and collected data of the
22 previous cohort study, implemented the biobank, and wrote the manuscript. AAS contributed
23 to implementation of HIPA, provided infrastructure, interpreted the analysis, and wrote the
24 manuscript. All authors approved the final version of the manuscript.

25 Acknowledgements

26 We are very grateful to Prof. Greinacher and his team at Greifswald University for his generous
27 support regarding implementation of HIPA at our institution. We thank Prof. M. Fiedler and
28 the Center of Laboratory Medicine at Inselspital for providing reagents, laboratory space as
29 well as technicians.

30 Funding

31 MN is supported by a research grant of the Swiss National Science Foundation (#179334).

32 Declaration of interest

33 All the authors state that they have no conflict of interest.

34

1 References

- 2 [1] M. Nagler, T. Bakchoul, Clinical and laboratory tests for the diagnosis of heparin-induced
3 thrombocytopenia, *Thrombosis and haemostasis* 116(5) (2016) 823-834.
- 4 [2] T.E. Warkentin, A. Greinacher, Y. Gruel, R.H. Aster, B.H. Chong, scientific, t. standardization
5 committee of the international society on, haemostasis, Laboratory testing for heparin-induced
6 thrombocytopenia: a conceptual framework and implications for diagnosis, *Journal of thrombosis
7 and haemostasis* : JTH 9(12) (2011) 2498-500.
- 8 [3] A. Cuker, P.A. Gimotty, M.A. Crowther, T.E. Warkentin, Predictive value of the 4Ts scoring system
9 for heparin-induced thrombocytopenia: a systematic review and meta-analysis, *Blood* 120(20) (2012)
10 4160-7.
- 11 [4] V. Minet, J.M. Dogne, F. Mullier, Functional Assays in the Diagnosis of Heparin-Induced
12 Thrombocytopenia: A Review, *Molecules* 22(4) (2017).
- 13 [5] A. Cuker, Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis,
14 *Thrombosis and haemostasis* 106(6) (2011) 993-4.
- 15 [6] T.E. Warkentin, L.A. Linkins, Immunoassays are not created equal, *Journal of thrombosis and
16 haemostasis* : JTH 7(8) (2009) 1256-9.
- 17 [7] M. Nagler, L.M. Bachmann, H. ten Cate, A. ten Cate-Hoek, Diagnostic value of immunoassays for
18 heparin-induced thrombocytopenia: a systematic review and meta-analysis, *Blood* 127(5) (2016) 546-
19 57.
- 20 [8] T. Bakchoul, H. Zollner, A. Greinacher, Current insights into the laboratory diagnosis of HIT,
21 *International journal of laboratory hematology* 36(3) (2014) 296-305.
- 22 [9] H. Stricker, B. Lammler, M. Furlan, I. Sulzer, Heparin-dependent in vitro aggregation of normal
23 platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare
24 side effect, *The American journal of medicine* 85(5) (1988) 721-4.
- 25 [10] V. Nellen, I. Sulzer, G. Barizzi, B. Lammler, L. Alberio, Rapid exclusion or confirmation of heparin-
26 induced thrombocytopenia: a single-center experience with 1,291 patients, *Haematologica* 97(1)
27 (2012) 89-97.
- 28 [11] A. Greinacher, J. Amiral, V. Dummel, A. Vissac, V. Kiefel, C. Mueller-Eckhardt, Laboratory
29 diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test,
30 heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked
31 immunosorbent assay, *Transfusion* 34(5) (1994) 381-5.
- 32 [12] B.H. Chong, J. Burgess, F. Ismail, The clinical usefulness of the platelet aggregation test for the
33 diagnosis of heparin-induced thrombocytopenia, *Thrombosis and haemostasis* 69(4) (1993) 344-50.
- 34 [13] E.J. Favaloro, E. Bernal-Hoyos, T. Exner, J. Koutts, Heparin-induced thrombocytopenia:
35 laboratory investigation and confirmation of diagnosis, *Pathology* 24(3) (1992) 177-83.

36